Better comms between academia and industry

As announced at our Grand Opening, we’ve launched into a big collaboration with AstraZeneca to use CRISPR for basic research aimed at impacting human health. Just as important, we’ve also just started a very exciting partnership with Agilent, providing access to technologies we’ve previously only dreamed about. So what are these collaborations all about? What do we hope to do? Why are we working with companies at all? 

I think this is all about two-way communication. From my time at Genentech, I know that industry certainly pays a lot of attention to what’s going on in academia (below I’m mostly talking about academics trying to directly make an impact for human health). But there’s also frustration, because some ideas are really great and then plow themselves right into the ground during execution. For example, a super-cool proof of concept that will has no chance of impacting patients because the [assay|intervention|etc] is unnecessarily jury-rigged or the [results|compounds|cells] weren’t discussed with anyone who might spend the next 12+ years to turn the idea into a therapy. Derek Lowe has any number of posts about these kinds of papers, and has strong words to say about most academic small molecule screens. In these cases, industry wistfully sighs, “If only they had done X, Y, or Z, we would be so excited to work with them to make it go further!” But unfortunately, there’s very little bandwidth for those kinds of long-term gambles in an industry lab (Genentech was an exception, thankfully for me). In this way, some academic work that aims to help people instead just nets the authors a cool paper and then dwindles away. This is incredibly frustrating for both sides, since everyone truly wants to make a positive impact on the world and 

That’s exactly what we want to avoid, and we’re going to do it with two-way communication and tight collaboration. What high-risk (e.g. academic) research needs to be done in the medium term to help better therapies get to patients faster? What are new and emerging areas where breakthrough science meets potential to impact health? What are the long-term moonshots that might actually get picked up and turned into a world-changing therapy if successful? Both academic and industry scientists have strong feelings about these questions, but all too often we exist in the monoculture of our immediate environment and fail to really communicate with one another.

The IGI’s collaborations with Agilent and AstraZeneca represents our first steps in the road to reversing this trend. We’ll be doing basic research together with groups from both companies, in a truly collaborative mode. We hope to both to give them insight into new and great scientific discoveries on the horizon, and also to get their insight into areas where basic research now can have a dramatic impact in the long term. I think that through collaborations with industry groups we can make a very positive impact in the fight against many diseases (stay tuned for more on the science!); it’s going to be an exciting time!

Jacob Corn

Jacob Corn is the Scientific Director of the IGI and faculty at UC Berkeley. Follow him on twitter @jcornlab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest Blog Posts

October 16, 2018 2 Comments

Bootstrapping a lab

Today I’m going to talk about setting up a lab from a 10,000 foot view. I got thinking about this because my social media feed was recently filled with people announcing...

June 12, 2017 1 Comment

Shapers and Mechanists

There’s a series of cyberpunk short stories and a book written in the 1980s by Bruce Sterling called The Schismatrix. It centers around two major offshoots...

June 1, 2017 1 Comment

Backpacking season

It’s important to spend time outside the lab. And before you ask, that’s not why the blog has been dormant. I was teaching this last semester (a general biochemistry...

Blog Archive

Tweets